(Q34300784)

1 August 2017

title

Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management (English)

1 reference

1 August 2017

Heikki Joensuu

1

1 reference

1 August 2017

publication date

1 October 2012

1 reference

1 August 2017

1 reference

1 August 2017

volume

72

1 reference

1 August 2017

issue

15

1 reference

1 August 2017

page(s)

1953-1963

1 reference

Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

High incidence of microscopic gastrointestinal stromal tumors in the stomach.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

An evaluation of 2537 gastrointestinal stromal tumors for a proposed clinical staging system

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Risk stratification of patients diagnosed with gastrointestinal stromal tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Surgical outcomes of gastrointestinal stromal tumors of the stomach: a single unit experience in the era of targeted drug therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Practical management of tyrosine kinase inhibitor-associated side effects in GIST.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Gastrointestinal stromal tumors: pathology and prognosis at different sites

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

An improved technique for mitosis counting

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

KRAS-mutation positive, metastatic tonsil carcinoma with cancer stem-like cell features and long-term response to gefitinib: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

The risks of radiation exposure related to diagnostic imaging and how to minimise them.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11635590-000000000-00000

Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months

21 January 2018

1 reference

12 December 2020

Diagnosis of gastrointestinal stromal tumors: A consensus approach

1 reference

12 December 2020

Adjuvant therapy in primary GIST: state-of-the-art

1 reference

12 December 2020

Surgical resection of gastrointestinal stromal tumors after treatment with imatinib

1 reference

12 December 2020

Imatinib as adjuvant treatment following resection of KIT-positive gastrointestinal stromal tumours

1 reference

12 December 2020

Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients

1 reference

12 December 2020

Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases

1 reference

12 December 2020

Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour – The impact of tumour rupture on patient outcomes

1 reference

12 December 2020

Gastrointestinal stromal tumours: origin and molecular oncology.

1 reference

12 December 2020

[Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial].

1 reference

12 December 2020

Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States

1 reference

12 December 2020

10.2165/11635590-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

1041041826

0 references

1 reference